RxDoctor Payments Data

Kimberly Green, DO

General Practice · Alpharetta, GANPI 1720174873

Payments from drug & device makers

$1,922in general payments, 2019–2025

Across 70 payments — averaging $27.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Indivior Inc.$920
  • Braeburn Inc.$722
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$90
  • Orexo US, Inc.$73
  • Emergent Biosolutions Inc.$45
  • Novo Nordisk$26
  • plus $46 from 2 others

What the payments were for

  • Food & beverage$1,921100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,922 in reported general payments places this provider in the 85th percentile of 2,542 general practice providers in Georgia.

See all general practice providers in Georgia

Medicare billing

Part B allowed, 2024
$40,904
Medicare patients
32
Services billed
324

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl87$143,580
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl138$31,191
SuboxoneBuprenorphine Hcl/Naloxone Hcl11$9,015
Oxycodone Hcl271$8,249
Morphine Sulfate ErMorphine Sulfate138$7,490
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen74$3,857
Buprenorphine Hcl75$3,209
Fentanyl27$2,625
Tizanidine Hcl59$1,665
Lidocaine21$1,559
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen74$1,505
Pregabalin99$1,166
Diclofenac Sodium29$1,054
Gabapentin69$802
Morphine Sulfate20$652

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Indivior Inc.Suboxone$920$9,01511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,542 general practice providers in Georgia.

Other general practice in Alpharetta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →